Molecular and biological factors in the pathogenesis of ovarian cancer

  • J. S. Berek
  • O. Martínez-Maza


Ovarian cancer, which results in higher mortality than any other gynecologic malignancy, is the fourth leading cause of cancer deaths in women in the United States [1]. A major factor in this high mortality is that at the time of diagnosis most patients already have advanced disease. Early detection in ovarian cancer is hampered by the lack of appropriate tumor markers and clinically, most ovarian cancer patients fail to develop significant symptoms until they reach advanced stage disease. Ovarian cancer has a high frequency of metastasis, yet generally remains localized within the peritoneal cavity [2].


Ovarian Cancer Epithelial Ovarian Cancer Ovarian Cancer Cell Ascitic Fluid Ovarian Cancer Patient 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Silverberg, E., Boring, C.C. and Squires, T.S. (1990). Cancer statistics 1990. Ca — A Cancer J. Clin., 40,9.CrossRefGoogle Scholar
  2. 2.
    Berek, J.S. (1994) Epithelial ovarian cancer. In Practical Gynecologic Oncology 2nd edn., (eds J.S. Berek and N.F. Hacker), Williams and Wilkins, Baltimore, p. 327.Google Scholar
  3. 3.
    Bookman, M.A. and Bast, R.C. Jr. (1991) Immunobiology and immunotherapy of ovarian cancer. Semin. Oncol., 18,270.PubMedGoogle Scholar
  4. 4.
    Bookman, M.A. and Berek, J.S. (1992) Biologic and immunologic therapy of ovarian cancer. Hematol Oncol Clin. North Am., 6,941.PubMedGoogle Scholar
  5. 5.
    Piver, M.S. (1987) Epidemiology of ovarian cancer. In Ovarian Malignancies: Diagnosis and Therapeutic Advances, (ed. M.S. Piver), Churchill Livingstone, Edinburgh, pp. 1–10.Google Scholar
  6. 6.
    Malik, S. and Balkwill, F. (1991) Epithelial ovarian cancer: a cytokine propelled disease? Br. J. Cancer, 64,617.PubMedCrossRefGoogle Scholar
  7. 7.
    Mills, G.B., Hashimoto, S., Hurteau, J. et al., (1992) Regulation of growth of human ovarian cancer cells. In Ovarian Cancer 2: Biology, Diagnosis and, W. Management, (eds F. Sharp, W.P. Mason and W. Creasman), Chapman & Hall, London, pp. 127–45.Google Scholar
  8. 8.
    Motro, B., Itin, A., Sachs, L. and Keshet, E. (1990) Pattern of interleukin 6 gene expression in vivo, suggests a role for this cytokine in angiogenesis. PN AS, 87,3092.PubMedCrossRefGoogle Scholar
  9. 9.
    Buyalos, R.P., Watson, J.M. and Martinez-Maza, O. (1992) Detection of interleukin-6 in human follicular fluid. Fertil. Steril, 57,1230.PubMedGoogle Scholar
  10. 10.
    Berchuck, A., Kohier, M.F. and Bast, R.C. Jr. (1992) Oncogenes in ovarian cancer. Hematol Oncol Clin. N. Am., 6,813.Google Scholar
  11. 11.
    Berchuck, A., Marks, J.R. and Bast, R.C. Jr. (1992) Expression of the epidermal growth factor receptor, HER-2/neu, and p53 in ovarian cancer. In Ovarian Cancer 2: Biology, Diagnosis and Management, (eds F. Sharp, W.P. Mason and W. Creasman), Chapman & Hall, London, pp. 53–9.Google Scholar
  12. 12.
    Kommoss, F., Bauknecht, T., Birmelin, G. et al, (1992) Oncogene and growth factor expression in ovarian cancer. Acta Obstet. Gynecol Scand., (Suppl.), 155,19.Google Scholar
  13. 13.
    Barletta, C., Lazzaro, D., Prosperi Porta, R. et al, (1992) c-myb, activation and the pathogenesis of ovarian cancer. Eur. J. Gynaecol Oncol., 13,53.PubMedGoogle Scholar
  14. 14.
    Baker, V.V., Borst, M.P., Dixon, D. et al, (1990) c-myc, amplification in ovarian cancer. Gynecol Oncol., 38,340.PubMedCrossRefGoogle Scholar
  15. 15.
    Boltz, E.M., Kefford, R.F., Leary, J.A. et al, (1989) Amplification of c-ras-Ki, oncogene in human ovarian tumours. Int. J. Cancer, 43,428.PubMedCrossRefGoogle Scholar
  16. 16.
    Zhou, D.J., Gonzalez-Cadavid, N., Ahuja, H. et al, (1988) A unique pattern of proto-oncogene abnormalities in ovarian adenocarcinomas. Cancer, 62,1573.PubMedCrossRefGoogle Scholar
  17. 17.
    Rodenburg, C.J., Koelma, I.A., Nap, M. and Fleuren, G.J. (1988) Immunohistochemical detection of the ras, oncogene product p21 in advanced ovarian cancer. Lack of correlation with clinical outcome. Arch. Pathol Lab. Med., 112,151.PubMedGoogle Scholar
  18. 18.
    Bishop, J.M. (1991) Molecular themes in oncogenesis. Cell, 64,235.PubMedCrossRefGoogle Scholar
  19. 19.
    Berchuck, A., Kamel, A., Whitaker, R. et al, (1990) Overexpression ofHER-2/neu, is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res., 50,4087.PubMedGoogle Scholar
  20. 20.
    Slamon, D.J., Godolphin, W., Jones, L.A. et al, (1989) Studies of HER-2/neu, proto-oncogene in human breast and ovarian cancer.Science, 244, 707.PubMedCrossRefGoogle Scholar
  21. 21.
    Lichtenstein, A., Berenson, J., Gera, J.F. et al, (1990) Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokineactivated killer cells: correlation with expression ofHER/neu, oncogenes. Cancer Res., 50, 7364.PubMedGoogle Scholar
  22. 22.
    Kokai, Y., Dobashi, K., Weiner, D.B. et al, (1988) Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu, (NGL) gene products. PNAS, 85, 5389.PubMedCrossRefGoogle Scholar
  23. 23.
    Peles, E., Bacus, S.S., Koshi, R.A. et al, (1992) Isolation of the neu/HER-2, stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell, 69,205.PubMedCrossRefGoogle Scholar
  24. 24.
    Kacinsky, B.M., Carter, D., Mittal, K. et al, (1990) Ovarian adenocarcinomas express fms,complementary transcripts and fms, antigen, often with co-expression of CSF-1. Am. J. Pathol., 137,135.Google Scholar
  25. 25.
    Ramakrishnan, S., Xu, F.J., Brandt, S.J. et al, (1989) Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines, J. Clin. Invest., 83, 921.PubMedCrossRefGoogle Scholar
  26. 26.
    Bast, R.C. Xu, F.J., Rodriguez, G.C. et al, (1992) Inhibition of breast and ovarian tumour cell growth by antibodies and immunotoxins reactive with distinct epitopes on the extracellular domain of HER-2/neu, (c-erbB2). In Ovarian Cancer 2: Biology, Diagnosis and Management, (eds F. Sharp, W. Mason and W. Creasman), Chapman & Hall, London, pp. 67–71.Google Scholar
  27. 27.
    Marks, J.R., Davidoff, A.M., Kerns, B.J. et al, (1991) Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res., 51, 2979.PubMedGoogle Scholar
  28. 28.
    Mazars, R., Pujol, P., Maudelonde, T. et al, (1991) p53 mutations in ovarian cancer: a late event? Oncogene, 6,1685.Google Scholar
  29. 29.
    Okamoto, A., Sameshima, Y., Yokoyama, S. et al, (1991) Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res., 51,5171.PubMedGoogle Scholar
  30. 30.
    Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C.C. (1991) p53 mutations in human cancers. Science, 253,49.PubMedCrossRefGoogle Scholar
  31. 31.
    Levine, A.J., Momand, J. and Finlay, C.A. (1991) The p53 tumour suppressor gene. Nature, 351,453.PubMedCrossRefGoogle Scholar
  32. 32.
    Gotlieb, W.H., Watson, J.M., Rezai, A. et al, (1994) Upregulation of p53 tumor suppressor gene expression by tumor necrosis factoralpha: relation to the production of apoptosis in an ovarian cancer cell line.Am. J. Obstet. Gynecol., 170,1121–30.PubMedGoogle Scholar
  33. 33.
    Li, S.B., Schwartz, P.E., Lee, W.H., Yang-Feng, T.L. (1991) Allele loss at the retinoblastoma locus in human ovarian cancer. J. Natl Cancer Inst., 83, 637.PubMedCrossRefGoogle Scholar
  34. 34.
    Aaronson, S.A. (1991) Growth factors and cancer. Science, 254,1146.PubMedCrossRefGoogle Scholar
  35. 35.
    Cross, M. and Dexter, T.M. (1991) Growth factors in development, transformation, and tumorigenesis. Cell, 64, 271.PubMedCrossRefGoogle Scholar
  36. 36.
    Malik, S., Naylor, M.S. and Balkwill, F.R. (1992) Cytokines and ovarian cancer. In Ovarian Cancer 2: Biology, Diagnosis and Management, (eds F. Sharp, W.P. Mason and W. Creasman), Chapman & Hall, London, pp. 87–92.Google Scholar
  37. 37.
    Martmez-Maza, O. and Berek, J.S. (1991). Interleukin 6 and cancer therapy. In Vivo, 5, 583.Google Scholar
  38. 38.
    Bast, R.C., Xu, F.J., Rodriguez, G.C. et al, (1992) Factors regulating the growth of normal and malignant ovarian epithelium. In Ovarian Cancer 2: Biology, Diagnosis and Management, (eds F. Sharp, W.P. Mason and W. Creasman), Chapman & Hall, London, pp. 61–6.Google Scholar
  39. 39.
    Wakefield, L.M. and Sporn, M.B. (1990). Suppression of carcinogenesis: a role for TGF-β, and related molecules in prevention of cancer. In Tumor Suppressor Genes, (ed. G. Klein), Marcel Dekker, New York, pp. 217–43.Google Scholar
  40. 40.
    Berek, J.S., Watson, J.M. and Martmez-Maza, O. (1992) Role of interleukin-6 in ovarian cancer. In Ovarian Cancer 2: Biology, Diagnosis and Management, (eds F. Sharp, W.P. Mason and W. Creasman), Chapman & Hall, London, pp. 101–13.Google Scholar
  41. 41.
    Carson, L.F., Moradi, M.M., Li, B.Y. et al, (1992) Characterization of cytokines produced by ovarian cancer cells. In Ovarian Cancer 2: Biology, Diagnosis and Management, (eds F. Sharp, W.P. Mason and W. Creasman), Chapman & Hall, London, pp. 93–9.Google Scholar
  42. 42.
    Kacinsky, B.M. (1992) CSF-1 and its receptor on ovarian and other gynaecological neoplasms. In Ovarian Cancer 2: Biology, Diagnosis and Management, (eds F. Sharp, W.P. Mason and W. Creasman), Chapman & Hall, London, pp. 115–25.Google Scholar
  43. 43.
    Wu, S., Rodabaugh, K., Watson, J.M. et al, (1992) Stimulation of ovarian tumor cell proliferation with monocyte products including IL-1-alpha, IL-6 and tumor necrosis factoralpha. Am. J. Obstet. Gynecol., 166, 997.PubMedGoogle Scholar
  44. 44.
    Kawano, M., Hirano, T., Matsuda, T. et al, (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature, 332, 83.PubMedCrossRefGoogle Scholar
  45. 45.
    Klein, B., Zhang, X.G., Jourdan, M. et al, (1989) Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood, 73, 517.PubMedGoogle Scholar
  46. 46.
    Miki, S., Iwano, M., Miki, Y. et al, (1989) Interleukin-6 (IL-6) functions as an in vitro, autocrine growth factor in renal cell carcinomas. FEBS Lett., 250,607.PubMedCrossRefGoogle Scholar
  47. 47.
    Miles, S.A., Rezai, A.R., Salazar-Gonzalez, J.F. et al, (1990) AIDS Kaposi’s sarcoma-derived cells produce and respond to interleukin-6. PN AS, 87,4068.PubMedCrossRefGoogle Scholar
  48. 48.
    Sabourin, L.A. and Hawley, R.G. (1990) Suppression of programmed death and Gl arrest in B-cell hybridomas by interleukin-6 is not accompanied by altered expression of immediate early response genes, J. Cell Physiol, 145,564.PubMedCrossRefGoogle Scholar
  49. 49.
    Watson, J., Sensintaffar, J. L., Berek, J.S. and Martmez-Maza, O. (1990) Constitutive production of interleukin 6 by ovarian cell lines and by primary ovarian tumor cultures. Cancer Res., 50, 6959.PubMedGoogle Scholar
  50. 50.
    Hirano, T., Akira, S. and Kishimoto, T. (1990) Biological and clinical aspects of interleukin 6. Immunol Today, 11,443.PubMedCrossRefGoogle Scholar
  51. 51.
    Kishimoto, T. and Hirano, T. (1988) Molecular regulation of B lymphocyte response. Ann. Rev. Immunol., 6,485.CrossRefGoogle Scholar
  52. 52.
    Yamasaki, K., Taga, T., Hirata, Y. et al, (1988) Cloning and expression of human interleukin-6 (BSF-2/IFNb2) receptor. Science, 241, 825.PubMedCrossRefGoogle Scholar
  53. 53.
    Watson, J.M., Berek, J.S. and Martinez-Mara, O. (1993) Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligonucleotides. Gynecol Oncol., 49, 8–15.PubMedCrossRefGoogle Scholar
  54. 54.
    Akira, S., Isshiki, H., Sugita, T. et al, (1990) A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J., 9, 1897.PubMedGoogle Scholar
  55. 55.
    Lidor, Y.J., Xu, F.I., Martmez-Maza, O. et al, (1993) Constitutive production of macrophage colony stimulating factor and IL-6 by human ovarian surface epithelial cells. Exp. Cell Res., 207, 332–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Berek, J.S., Chung, C., Kaldi, K. et al, (1991) Serum IL-6 levels correlate with disease status in epithelial ovarian cancer patients. Am. J. Obstet. Gynecol., 164,1038.PubMedGoogle Scholar
  57. 57.
    Marinkovic, S., Jahreis, G.P., Wong, G.G. and Baumann, H. (1989) IL-6 modulates the synthesis of a specific set of acute phase plasma proteins in vivo. J. Immunol., 142, 808.Google Scholar
  58. 58.
    Stenson, R., Watson, J.M., Korzeniowski, P.A. et al, (1991) Generation, characterization and growth in nude mice of two ovarian tumor cell lines. Abstract, Society of Gynecological Investigation meeting.Google Scholar
  59. 59.
    Tosato, G., Seamon, K.B., Goldman, N.D. et al, (1988) Identification of a monocyte-derived human B cell growth factor as interferon-b2 (BSF-2, IL-6). Science, 239, 502.PubMedCrossRefGoogle Scholar
  60. 60.
    Ray, A., Tatter, S.B., Santhanam, U. et al, (1989) Regulation of expression of interleukin-6: molecular and clinical studies. Ann. NY Acad. Sci., 557, 353.PubMedCrossRefGoogle Scholar
  61. 61.
    Johnson, M.T., Watson, J.M., Berek, J.S. and Martmez-Maza, O. (1992) Interleukin-6 induces resistance of ovarian tumors to natural killer cell-mediated cytotoxicity. Proc. Soc. Gynecol Invest., Abstract.Google Scholar
  62. 62.
    Berek, J.S., Bast, R.C., Lichtenstein, A. et al, (1984) Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer. Ohstet. Gynecol., 64, 708.Google Scholar
  63. 63.
    Badger, A., Oh, S. and Moolten, F. (1981) Differential effects of an immunosuppressive fraction from ascites fluid of patients with ovarian cancer on spontaneous and antibody dependent cytotoxicity.Cancer Res., 41,1133.PubMedGoogle Scholar
  64. 64.
    Johnson, M.T., Sensintaffar, J.L., Watson, J.M. et al, (1991) Detection and preliminary characterization of an immune suppressive factor in ascites from women with ovarian cancer. Proc. Soc. Gynecol Invest., Abstract. Google Scholar
  65. 65.
    Gotlieb, W.H., Abrams, J.S., Watson, J.M. et al, (1992) Presence of IL-10 in the ascites of patients with ovarian and other intraabdominal cancers.Cytokine, 4,385–90.PubMedCrossRefGoogle Scholar
  66. 66.
    Fiorentino, D.F., Bond, M.W. and Mosmann, T.R. (1989) Two types of mouse helper T cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Thl clones. J. Exp. Med., 170,2081.PubMedCrossRefGoogle Scholar
  67. 67.
    Moore, K.W., Vieira, P., Fiorentino, D.F. et al, (1990) Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science, 248,1230.PubMedCrossRefGoogle Scholar
  68. 68.
    Mosmann, T.R. and Moore, K.W. (1991) The role of IL-10 in crossregulation of THl and TH2 responses. Immunol Today, 12, A49.PubMedCrossRefGoogle Scholar
  69. 69.
    Fiorentino, D.F., Zlotnik, A., Vieira, P. et al, (1991) IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Thl cells, J., Immunol., 146,3444.PubMedGoogle Scholar
  70. 70.
    Del Prete, G.F., de Carli, M., Ricci, M. and Romagnani, S. (1991) Helper activity for immunoglobulin synthesis of T helper type 1 (Th 1) and Th2 human T cell clones: the help of Thl clones is limited by their cytolytic capacity. J. Exp. Med., 174, 809.PubMedCrossRefGoogle Scholar
  71. 71.
    Romagnani, S. (1991) Human THl and TH2 subsets: doubt no more. Immunol. Today, 12, 256.PubMedCrossRefGoogle Scholar
  72. 72.
    Zlotnik, A. and Moore, K.W. (1991) Interleukin 10. Cytokine, 3,366.PubMedCrossRefGoogle Scholar
  73. 73.
    Bogdan, C, Vodovotz, Y. and Nathan, C. (1991) Macrophage deactivation by IL-10. J. Exp. Med., 174,1549.PubMedCrossRefGoogle Scholar
  74. 74.
    De Waal Malefyt, R., Abrams, J., Bennett, B. et al, (1991) IL-10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes, J. Exp. Med., 174,1209–20.CrossRefGoogle Scholar
  75. 75.
    Fiorentino, D.F., Zlotnik, A., Mosmann, T.R. et al, (1991) IL-10 inhibits cytokine production by activated macrophages, J. Immunol., 147, 3815.PubMedGoogle Scholar
  76. 76.
    Watson, J.M., Gotlieb, W.H., Abrams, J.H. et al, (1993) Immune analysis of ascitic fluid from patients with ovarian cancer: relationship between cytokines, acute phase proteins, immunoglobulins, immunosuppression and tumor classification. Proc. Soc. Gynecol Invest., 186 (abstract), 8.Google Scholar

Copyright information

© Chapman & Hall 1995

Authors and Affiliations

  • J. S. Berek
  • O. Martínez-Maza

There are no affiliations available

Personalised recommendations